Decision Resources, Inc., announces the publication of Strategic Overview of Vaccine Development, a recent study that maps areas of opportunity in vaccine development and offers strategies and analysis to guide vaccine developers on how to profit from recent innovations in vaccine technology.

(Photo: )

Companies vying for success in the vaccine marketplace face significant challenges. However, over the next decade, we believe that four indications- human immunodeficiency virus (HIV), hepatitis C virus (HCV), influenza, and pneumococcal diseases-will provide significant commercial opportunity for vaccine manufacturers in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Recent innovations in vaccine technology, including novel intranasal delivery techniques and cutting-edge DNA and virosomal vaccine technologies, and advances in understanding of immunity and pathogen resistance make the vaccine marketplace a dynamic and potentially lucrative sector. Physicians and public health officials are eager to use vaccination as a primary tool for infectious disease prevention. Researchers have taken particular interest in using therapeutic vaccines to potentially boost the immune response against infections that elicit poor immunologic control. Strong interest from all sides means vaccine manufacturers have unprecedented market opportunity.

In Strategic Overview of Vaccine Development, we identify the most important barriers and the most promising areas of opportunity in vaccine development for four therapeutic indications. Our findings including the following:

* The dramatic rise in prevalence of antibiotic-resistant pneumococci has sparked interest in both increasing pneumococcal vaccination rates and developing more effective vaccines. The recent launch of the first pediatric pneumococcal vaccine (Wyeth-Lederle's Prevnar/Prevenar) has established a precedent for future pneumococcal vaccines and opened untapped opportunities in the pediatric segment.

* Advances in our understanding of HIV and HCV are fueling research and providing promising vaccine approaches.

* Physicians recognize the high morbidity, mortality, and health care costs associated with influenza and are taking an increasingly active approach to influenza prevention. Several advances, including intranasal delivery systems, more potent adjuvanted inactivated vaccines, and innovative vaccine manufacturing technology, will fuel growth over our 2000-2010 forecast period.

Strategic Overview of Vaccine Development offers invaluable market intelligence for pharmaceutical companies competing in this arena. This study is part of the Infectious Disease portfolio, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

  Contact: Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or   In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347    (fax), or   In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617    (fax), or 


AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,

Eli Lilly's Xigris Could Lead the Way in Revolutionizing the Treatment Of Severe Sepsis and Septic Shock, According to a Decision Resources Study

View Now